Key Takeaways
- Shares of PBM climbed 203.8% on April 16, 2026, following reports the White House will issue an executive order advancing ibogaine research initiatives.
- Psyence Biomedical broadened its clinical trial infrastructure in Australia, adding two additional sites to support its NPX-5 Phase IIb psilocybin study.
- The biotech firm postponed a planned 1-for-6.25 reverse stock split, allowing shares to continue trading without adjustment.
- Market analysts attribute the surge to speculative trading in a thinly-traded micro-cap rather than material business developments.
- With a market capitalization of $11.63 million and a GF Score of 20/100, PBM earns only 1/10 for profitability metrics.
Shares of Psyence Biomedical (PBM) experienced extraordinary volatility on April 16, 2026. The stock rocketed more than 200% higher as traders reacted to breaking news that the White House intends to issue an executive order supporting ibogaine research, a psychedelic substance being explored for PTSD and mental health applications.
According to Quiver PriceTracker, PBM finished trading up roughly 203.8% by the closing bell. GuruFocus data showed intraday peaks reaching approximately 105.96%.
The White House announcement represents a notable policy evolution regarding psychedelic therapeutics at the federal level. Ibogaine has attracted attention from researchers studying its potential in addressing addiction disorders and psychological trauma, and the forthcoming executive order would accelerate scientific investigation.
While PBM’s primary focus centers on natural psilocybin rather than ibogaine directly, the positive regulatory momentum across the psychedelic sector generated significant upward pressure on the stock.
Australian Trial Network Expands Operations
Beyond the favorable policy news, PBM unveiled company-specific developments. The firm announced expansion of its Australian clinical trial infrastructure from three locations to five. This enhancement supports continued Phase IIb activities for NPX-5, the company’s naturally-derived psilocybin candidate being evaluated for Adjustment Disorder in cancer patients under palliative care.
This network expansion aims to accelerate patient enrollment and maintain dosing continuity throughout the program. The company disclosed these details through an SEC Form 6-K filing in April 2026.
Importantly, April 16 brought no fresh efficacy results or safety updates. Market observers characterize the price action as momentum-based, with limited trading volume magnifying the percentage gains.
Additionally, PBM announced it had delayed its previously scheduled 1-for-6.25 reverse stock split. Shares will continue trading on their current basis until management sets a new implementation date. This decision maintained the existing share structure and may have contributed to the volatile price movement.
Financial Profile and Market Metrics
Psyence Biomedical operates as a micro-cap biotech with total market capitalization of approximately $11.63 million. Prior to the surge, shares traded near $5.08—significantly below the 52-week peak of $74.94.
The company’s GF Score registers at 20 out of 100. While financial strength achieves an 8/10 rating, profitability scores only 1/10. The absence of a P/E ratio reflects ongoing losses.
Institutional participation remains minimal. During Q4 2025, five institutional holders reduced or eliminated their positions entirely. Parallel Advisors liquidated its complete stake of 151,250 shares. UBS Group represented the only new institutional buyer, acquiring 1,007 shares.
Company insiders have reported zero buying or selling activity over the trailing twelve months.
Psyence Biomedical maintains a federally-licensed psilocybin cultivation operation in Southern Africa, supplying research partners internationally.
As of April 16, 2026, the company generates no revenue and remains unprofitable while advancing its mid-stage clinical programs.
